search
Back to results

Sleep for Health Study on the Effects of Cognitive Behavioral Therapy for Insomnia on Diabetes Risk

Primary Purpose

Diabetes Mellitus, Type 2, Prediabetic State, Sleep Initiation and Maintenance Disorders

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
SHUTi
Patient Education
Sponsored by
Kaiser Permanente
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

22 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age ≥ 22 years and < 80 years of age Prediabetes Insomnia Regular access to device with internet access Adequate data at baseline Exclusion Criteria: BMI > 40 kg/m2 Sleep comorbidities detected in medical record or via medical history Shift work or significant, externally imposed irregular sleep schedule OSA by home sleep apnea test as part of trial protocol Received a full course of CBT-I in the last 12 months Current use of medication with glycemic effects: History of type 1 or type 2 diabetes or recent/planned use of hypoglycemic agents (e.g., metformin, insulin) Recent history of bariatric surgery or planning bariatric surgery in the next year Current or recent use of weight loss meds Unstable sleep medication regimen (recent change to schedule or dosage) Significant comorbidity that may interfere with CBT-I uptake or increase risks Unwilling or unable to limit heavy machinery use/long bouts of driving or unstable illness that would be worsened by sleep restriction High risk of falls Epilepsy Medical conditions that interfere with dCBT-I or contribute to insomnia or diabetes risk (e.g., hyperthyroidism, significant kidney disease, active cancer treatment, any medical condition that requires chronic steroid use) Significant alcohol or substance use disorder Active or recent history of eating disorder, recent weight change of >10% Women: pregnancy (current or planned), breastfeeding, < 1 year postpartum Use of hydroxyurea Extensive skin changes or adhesive allergy making CGM sensor use problematic

Sites / Locations

  • Kaiser Permanente Center for Health ResearchRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Digital cognitive behavioral therapy (dCBT-I)

Patient Education (PE)

Arm Description

CBT-I is designed to change sleep habits and scheduling factors that affect sleep, and to address misconceptions about sleep and insomnia that perpetuate sleep difficulties. The investigators will employ SHUTi, which is an extensively studied dCBT-I program. SHUTi is intended to improve insomnia symptoms by providing neurobehavioral intervention (cognitive behavioral therapy for insomnia - CBT-I) in adults with chronic insomnia. It is a six-core internet-delivered CBT-I web-based app that is run through a browser. It is accessible via iPhone/iPad, Android phone/tablet, computer or laptop (any device with a browser). SHUTi follows evidence-based CBT-I principles.

Participants will be given access to a patient education website. It will provide nontailored material about insomnia symptoms; the impact, prevalence, and causes of insomnia; and basic lifestyle, environmental, and behavioral strategies to improve sleep.

Outcomes

Primary Outcome Measures

2-hour post-load glucose (2hPG) (mg/dL)
2-hour post-load glucose (mg/dL)

Secondary Outcome Measures

Hemoglobin A1c (A1C) (percentage)
Plasma HgB A1C (percentage)
Fasting plasma glucose (FPG) (mg/dL)
Fasting plasma glucose levels (mg/dL)
Mean glucose on CGM (mg/dL)
Average blood glucose levels throughout CGM wear duration (mg/dL)
Insulin resistance score (probability ranking, Calculated using the insulin and C-peptide concentrations converted to pmol/L)
Insulin resistance score - (probability ranking, Calculated using the insulin and C-peptide concentrations converted to pmol/L)

Full Information

First Posted
July 31, 2023
Last Updated
September 27, 2023
Sponsor
Kaiser Permanente
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT06067139
Brief Title
Sleep for Health Study on the Effects of Cognitive Behavioral Therapy for Insomnia on Diabetes Risk
Official Title
Sleep for Health: A Randomized Clinical Trial Examining the Effects of Cognitive Behavioral Therapy for Insomnia on Diabetes Risk
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2023 (Actual)
Primary Completion Date
December 2026 (Anticipated)
Study Completion Date
March 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kaiser Permanente
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study tests whether providing cognitive behavioral therapy for insomnia (CBT-I) to people with prediabetes results in a reduction in glucose levels compared to a patient education control program.
Detailed Description
Type 2 diabetes mellitus (T2D) is a major cause of blindness, kidney failure, cardiovascular disease, amputations, reduced quality of life, and premature death in the United States, and it is expected that one in three Americans will have T2D by 2050. To stem the tide of this health crisis, new strategies are needed to prevent the progression to T2D from prediabetes-elevated glucose levels that are not yet in the diabetes range. A growing body of research suggests that insomnia is a major modifiable risk factor for progression to diabetes. The proposed study would build off a promising feasibility study to test whether providing cognitive behavioral therapy for insomnia (CBT-I) to patients with prediabetes results in a reduction in glucose levels compared to a patient education control program. If so, this insomnia treatment could be an effective tool to prevent diabetes. Individuals with prediabetes and insomnia will be randomized to receive six sessions of a deployment-ready digital CBT-I program, providing standard-of-care treatment for insomnia (intervention arm, n = 150), or a patient education website providing nontailored material about insomnia (control arm, n = 150). The investigators will complete assessments at baseline, at 11 weeks (after the conclusion of the intervention and control programs), and at 33 weeks post-baseline, measuring hyperglycemia, objective and subjective measures of sleep, and potential mediating variables including diet, exercise, and mood. The investigators will assess (1) whether individuals randomized to the intervention arm have lower rates of hyperglycemia, as measured by oral glucose tolerance testing and various secondary measures, than individuals randomized to the control arm at 11 weeks and 33 weeks after baseline; (2) whether improvements in sleep after baseline are associated with decreases in hyperglycemia, regardless of study arm; and (3) whether any effects of the intervention on hyperglycemia are mediated by improvements in sleep, diet, exercise, and/or mood. This research will serve as a critical step in identifying a potentially dramatic tool for improving health outcomes for Americans at risk of T2DM. Sleep interventions can lead to sustained improvements that are intrinsically rewarding to patients. If effective, digital CBT-I could provide a powerful pathway to preventing diabetes for millions of patients with prediabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2, Prediabetic State, Sleep Initiation and Maintenance Disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Digital cognitive behavioral therapy (dCBT-I)
Arm Type
Experimental
Arm Description
CBT-I is designed to change sleep habits and scheduling factors that affect sleep, and to address misconceptions about sleep and insomnia that perpetuate sleep difficulties. The investigators will employ SHUTi, which is an extensively studied dCBT-I program. SHUTi is intended to improve insomnia symptoms by providing neurobehavioral intervention (cognitive behavioral therapy for insomnia - CBT-I) in adults with chronic insomnia. It is a six-core internet-delivered CBT-I web-based app that is run through a browser. It is accessible via iPhone/iPad, Android phone/tablet, computer or laptop (any device with a browser). SHUTi follows evidence-based CBT-I principles.
Arm Title
Patient Education (PE)
Arm Type
Active Comparator
Arm Description
Participants will be given access to a patient education website. It will provide nontailored material about insomnia symptoms; the impact, prevalence, and causes of insomnia; and basic lifestyle, environmental, and behavioral strategies to improve sleep.
Intervention Type
Other
Intervention Name(s)
SHUTi
Intervention Description
Each core includes a variety of interactive features, such as animations, vignettes, "myth" and "reality" buttons that reveal common misperceptions and facts about sleep, "learn more" buttons that provide in-depth information about a topic, and quizzes. All cores follow a similar structure with objectives, main content, homework, and review. Participants are free to revisit cores as many times as they like.
Intervention Type
Other
Intervention Name(s)
Patient Education
Intervention Description
The PE website will present content in a simple, static form, without interactive components; and all content on the website will be provided at once, rather than in modules that unlock over time. The PE website will also not provide personalized or individually tailored treatment recommendations.
Primary Outcome Measure Information:
Title
2-hour post-load glucose (2hPG) (mg/dL)
Description
2-hour post-load glucose (mg/dL)
Time Frame
V1 (baseline), V2 (11 weeks after randomization), V3 (33 weeks from randomization)
Secondary Outcome Measure Information:
Title
Hemoglobin A1c (A1C) (percentage)
Description
Plasma HgB A1C (percentage)
Time Frame
V1 (baseline), V2 (11 weeks after randomization), V3 (33 weeks from randomization)
Title
Fasting plasma glucose (FPG) (mg/dL)
Description
Fasting plasma glucose levels (mg/dL)
Time Frame
V1 (baseline), V2 (11 weeks after randomization), V3 (33 weeks from randomization)
Title
Mean glucose on CGM (mg/dL)
Description
Average blood glucose levels throughout CGM wear duration (mg/dL)
Time Frame
V1 (baseline), V2 (11 weeks after randomization), V3 (33 weeks from randomization)
Title
Insulin resistance score (probability ranking, Calculated using the insulin and C-peptide concentrations converted to pmol/L)
Description
Insulin resistance score - (probability ranking, Calculated using the insulin and C-peptide concentrations converted to pmol/L)
Time Frame
V1 (baseline), V2 (11 weeks after randomization), V3 (33 weeks from randomization)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 22 years and < 80 years of age Prediabetes Insomnia Regular access to device with internet access Adequate data at baseline Exclusion Criteria: BMI > 40 kg/m2 Sleep comorbidities detected in medical record or via medical history Shift work or significant, externally imposed irregular sleep schedule OSA by home sleep apnea test as part of trial protocol Received a full course of CBT-I in the last 12 months Current use of medication with glycemic effects: History of type 1 or type 2 diabetes or recent/planned use of hypoglycemic agents (e.g., metformin, insulin) Recent history of bariatric surgery or planning bariatric surgery in the next year Current or recent use of weight loss meds Unstable sleep medication regimen (recent change to schedule or dosage) Significant comorbidity that may interfere with CBT-I uptake or increase risks Unwilling or unable to limit heavy machinery use/long bouts of driving or unstable illness that would be worsened by sleep restriction High risk of falls Epilepsy Medical conditions that interfere with dCBT-I or contribute to insomnia or diabetes risk (e.g., hyperthyroidism, significant kidney disease, active cancer treatment, any medical condition that requires chronic steroid use) Significant alcohol or substance use disorder Active or recent history of eating disorder, recent weight change of >10% Women: pregnancy (current or planned), breastfeeding, < 1 year postpartum Use of hydroxyurea Extensive skin changes or adhesive allergy making CGM sensor use problematic
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stefan Massimino, MS
Phone
971-232-9343
Email
stefan.massimino@kpchr.org
First Name & Middle Initial & Last Name or Official Title & Degree
Chris Catlin
Phone
971-369-0655
Email
chris.l.catlin@kpchr.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Erin LeBlanc, MD
Organizational Affiliation
Kaiser Permanente
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kaiser Permanente Center for Health Research
City
Portland
State/Province
Oregon
ZIP/Postal Code
97227
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefan Massimino, MS
Phone
971-232-9343
Email
stefan.massimino@kpchr.org
First Name & Middle Initial & Last Name & Degree
Chris Catlin
Phone
971-369-0655
Email
chris.l.catlin@kpchr.org
First Name & Middle Initial & Last Name & Degree
Erin LeBlanc, MD
First Name & Middle Initial & Last Name & Degree
Greg Clarke, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is not a plan to make individual participant data (IPD) available to other researchers after the end of the study.
Citations:
PubMed Identifier
22683128
Citation
Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012 Jun 16;379(9833):2279-90. doi: 10.1016/S0140-6736(12)60283-9. Epub 2012 Jun 9.
Results Reference
background
PubMed Identifier
31992061
Citation
Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 3;141(9):e139-e596. doi: 10.1161/CIR.0000000000000757. Epub 2020 Jan 29.
Results Reference
background
Citation
Centers for Disease Control and Prevention. Diabetes Report Card 2014. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services, 2015.
Results Reference
background
PubMed Identifier
30687505
Citation
LeBlanc ES, Smith NX, Nichols GA, Allison MJ, Clarke GN. Insomnia is associated with an increased risk of type 2 diabetes in the clinical setting. BMJ Open Diabetes Res Care. 2018 Dec 26;6(1):e000604. doi: 10.1136/bmjdrc-2018-000604. eCollection 2018.
Results Reference
background
PubMed Identifier
26687279
Citation
Anothaisintawee T, Reutrakul S, Van Cauter E, Thakkinstian A. Sleep disturbances compared to traditional risk factors for diabetes development: Systematic review and meta-analysis. Sleep Med Rev. 2016 Dec;30:11-24. doi: 10.1016/j.smrv.2015.10.002. Epub 2015 Oct 21.
Results Reference
background
PubMed Identifier
19910503
Citation
Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2010 Feb;33(2):414-20. doi: 10.2337/dc09-1124. Epub 2009 Nov 12.
Results Reference
background
PubMed Identifier
10179908
Citation
Hatoum HT, Kania CM, Kong SX, Wong JM, Mendelson WB. Prevalence of insomnia: a survey of the enrollees at five managed care organizations. Am J Manag Care. 1998 Jan;4(1):79-86.
Results Reference
background
PubMed Identifier
10543671
Citation
Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999 Oct 23;354(9188):1435-9. doi: 10.1016/S0140-6736(99)01376-8.
Results Reference
background
PubMed Identifier
20414467
Citation
van Leeuwen WM, Hublin C, Sallinen M, Harma M, Hirvonen A, Porkka-Heiskanen T. Prolonged sleep restriction affects glucose metabolism in healthy young men. Int J Endocrinol. 2010;2010:108641. doi: 10.1155/2010/108641. Epub 2010 Apr 19.
Results Reference
background
PubMed Identifier
24458353
Citation
Leproult R, Holmback U, Van Cauter E. Circadian misalignment augments markers of insulin resistance and inflammation, independently of sleep loss. Diabetes. 2014 Jun;63(6):1860-9. doi: 10.2337/db13-1546. Epub 2014 Jan 23.
Results Reference
background
PubMed Identifier
19542260
Citation
Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. Chest. 2010 Jan;137(1):95-101. doi: 10.1378/chest.09-0791. Epub 2009 Jun 19.
Results Reference
background
PubMed Identifier
20585000
Citation
Buxton OM, Pavlova M, Reid EW, Wang W, Simonson DC, Adler GK. Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes. 2010 Sep;59(9):2126-33. doi: 10.2337/db09-0699. Epub 2010 Jun 28.
Results Reference
background
PubMed Identifier
21921296
Citation
Gale JE, Cox HI, Qian J, Block GD, Colwell CS, Matveyenko AV. Disruption of circadian rhythms accelerates development of diabetes through pancreatic beta-cell loss and dysfunction. J Biol Rhythms. 2011 Oct;26(5):423-33. doi: 10.1177/0748730411416341.
Results Reference
background
PubMed Identifier
19056602
Citation
Nedeltcheva AV, Kilkus JM, Imperial J, Kasza K, Schoeller DA, Penev PD. Sleep curtailment is accompanied by increased intake of calories from snacks. Am J Clin Nutr. 2009 Jan;89(1):126-33. doi: 10.3945/ajcn.2008.26574. Epub 2008 Dec 3.
Results Reference
background
PubMed Identifier
18239586
Citation
Patel SR, Hu FB. Short sleep duration and weight gain: a systematic review. Obesity (Silver Spring). 2008 Mar;16(3):643-53. doi: 10.1038/oby.2007.118. Epub 2008 Jan 17.
Results Reference
background
PubMed Identifier
19849803
Citation
Patel SR. Reduced sleep as an obesity risk factor. Obes Rev. 2009 Nov;10 Suppl 2:61-8. doi: 10.1111/j.1467-789X.2009.00664.x.
Results Reference
background
PubMed Identifier
18936766
Citation
Patel SR, Blackwell T, Redline S, Ancoli-Israel S, Cauley JA, Hillier TA, Lewis CE, Orwoll ES, Stefanick ML, Taylor BC, Yaffe K, Stone KL; Osteoporotic Fractures in Men Research Group; Study of Osteoporotic Fractures Research Group. The association between sleep duration and obesity in older adults. Int J Obes (Lond). 2008 Dec;32(12):1825-34. doi: 10.1038/ijo.2008.198. Epub 2008 Oct 21.
Results Reference
background
PubMed Identifier
21996665
Citation
Booth JN, Bromley LE, Darukhanavala AP, Whitmore HR, Imperial JG, Penev PD. Reduced physical activity in adults at risk for type 2 diabetes who curtail their sleep. Obesity (Silver Spring). 2012 Feb;20(2):278-84. doi: 10.1038/oby.2011.306. Epub 2011 Oct 13.
Results Reference
background
PubMed Identifier
26786578
Citation
Broussard JL, Wroblewski K, Kilkus JM, Tasali E. Two Nights of Recovery Sleep Reverses the Effects of Short-term Sleep Restriction on Diabetes Risk. Diabetes Care. 2016 Mar;39(3):e40-1. doi: 10.2337/dc15-2214. Epub 2016 Jan 19. No abstract available.
Results Reference
background
PubMed Identifier
30408889
Citation
Thiesse L, Rudzik F, Spiegel K, Leproult R, Pieren R, Wunderli JM, Foraster M, Heritier H, Eze IC, Meyer M, Vienneau D, Brink M, Probst-Hensch N, Roosli M, Cajochen C. Adverse impact of nocturnal transportation noise on glucose regulation in healthy young adults: Effect of different noise scenarios. Environ Int. 2018 Dec;121(Pt 1):1011-1023. doi: 10.1016/j.envint.2018.05.036. Epub 2018 Jul 4.
Results Reference
background
PubMed Identifier
23589584
Citation
Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013 May 1;177(9):1006-14. doi: 10.1093/aje/kws342. Epub 2013 Apr 14.
Results Reference
background
PubMed Identifier
29458695
Citation
Cho YW, Kim KT, Moon HJ, Korostyshevskiy VR, Motamedi GK, Yang KI. Comorbid Insomnia With Obstructive Sleep Apnea: Clinical Characteristics and Risk Factors. J Clin Sleep Med. 2018 Mar 15;14(3):409-417. doi: 10.5664/jcsm.6988.
Results Reference
background
PubMed Identifier
33298414
Citation
American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S34-S39. doi: 10.2337/dc21-S003.
Results Reference
background
PubMed Identifier
15657324
Citation
Asarnow JR, Jaycox LH, Duan N, LaBorde AP, Rea MM, Murray P, Anderson M, Landon C, Tang L, Wells KB. Effectiveness of a quality improvement intervention for adolescent depression in primary care clinics: a randomized controlled trial. JAMA. 2005 Jan 19;293(3):311-9. doi: 10.1001/jama.293.3.311.
Results Reference
background
PubMed Identifier
11092283
Citation
The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care. 2000 Nov;23(11):1619-29. doi: 10.2337/diacare.23.11.1619.
Results Reference
background
PubMed Identifier
19567526
Citation
Nedeltcheva AV, Kessler L, Imperial J, Penev PD. Exposure to recurrent sleep restriction in the setting of high caloric intake and physical inactivity results in increased insulin resistance and reduced glucose tolerance. J Clin Endocrinol Metab. 2009 Sep;94(9):3242-50. doi: 10.1210/jc.2009-0483. Epub 2009 Jun 30.
Results Reference
background
PubMed Identifier
14633807
Citation
Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003 Dec;26(12):3230-6. doi: 10.2337/diacare.26.12.3230.
Results Reference
background
PubMed Identifier
33383394
Citation
Kothari V, Cardona Z, Chirakalwasan N, Anothaisintawee T, Reutrakul S. Sleep interventions and glucose metabolism: systematic review and meta-analysis. Sleep Med. 2021 Feb;78:24-35. doi: 10.1016/j.sleep.2020.11.035. Epub 2020 Dec 7.
Results Reference
background
PubMed Identifier
11832527
Citation
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512.
Results Reference
background
PubMed Identifier
24876580
Citation
Hanefeld M, Sulk S, Helbig M, Thomas A, Kohler C. Differences in Glycemic Variability Between Normoglycemic and Prediabetic Subjects. J Diabetes Sci Technol. 2014 Mar;8(2):286-290. doi: 10.1177/1932296814522739. Epub 2014 Mar 2.
Results Reference
background
Citation
Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed: Lawrence Erlbaum Associates; 1988.
Results Reference
background
Citation
Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons, Inc.; 1987.
Results Reference
background
PubMed Identifier
17053485
Citation
Krishnan V, Collop NA. Gender differences in sleep disorders. Curr Opin Pulm Med. 2006 Nov;12(6):383-9. doi: 10.1097/01.mcp.0000245705.69440.6a.
Results Reference
background
PubMed Identifier
26168121
Citation
Nosek BA, Spies JR, Motyl M. Scientific Utopia: II. Restructuring Incentives and Practices to Promote Truth Over Publishability. Perspect Psychol Sci. 2012 Nov;7(6):615-31. doi: 10.1177/1745691612459058.
Results Reference
background
Links:
URL
http://dbcms.s3.amazonaws.com/media/files/80cc1018-d357-49de-91df-2bd298499dc2/what%20is%20prediabetes.pdf
Description
Diabetes Care and Education Dietetic Practice Group. What is pre-diabetes?
URL
http://professional.diabetes.org/
Description
American Diabetes Association. All about pre-diabetes. Toolkit No. 3 2012
URL
https://provider.dexcom.com/faqs-categories/dexcom-g6-pro
Description
Dexcom G6 Pro

Learn more about this trial

Sleep for Health Study on the Effects of Cognitive Behavioral Therapy for Insomnia on Diabetes Risk

We'll reach out to this number within 24 hrs